Cantor Fitzgerald Analysts Give Endo International (ENDP) a $7.00 Price Target

Endo International (NASDAQ:ENDP) (TSE:ENL) has been given a $7.00 price objective by equities research analysts at Cantor Fitzgerald in a research note issued to investors on Thursday. The brokerage currently has a “hold” rating on the stock. Cantor Fitzgerald’s target price indicates a potential downside of 11.73% from the company’s previous close.

A number of other analysts have also commented on the stock. Zacks Investment Research raised shares of Endo International from a “hold” rating to a “buy” rating and set a $9.75 price objective for the company in a research note on Wednesday, October 11th. Mizuho reaffirmed a “buy” rating on shares of Endo International in a research note on Friday, November 10th. Royal Bank of Canada reduced their price objective on shares of Endo International from $9.00 to $8.00 and set a “sector perform” rating for the company in a research note on Friday, November 10th. BidaskClub raised shares of Endo International from a “sell” rating to a “hold” rating in a research note on Tuesday, December 12th. Finally, Vetr raised shares of Endo International from a “buy” rating to a “strong-buy” rating and set a $8.92 price objective for the company in a research note on Tuesday, December 26th. Two equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $11.27.

Shares of Endo International (NASDAQ ENDP) traded down $0.14 during midday trading on Thursday, reaching $7.93. 4,420,000 shares of the company’s stock were exchanged, compared to its average volume of 4,840,000. Endo International has a 52 week low of $5.77 and a 52 week high of $15.47. The company has a quick ratio of 0.86, a current ratio of 1.08 and a debt-to-equity ratio of 10.78. The firm has a market cap of $1,800.00, a P/E ratio of -0.41, a price-to-earnings-growth ratio of 2.98 and a beta of 0.59.

Endo International (NASDAQ:ENDP) (TSE:ENL) last issued its quarterly earnings results on Thursday, November 9th. The company reported $0.91 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.85 by $0.06. Endo International had a negative net margin of 126.97% and a positive return on equity of 66.98%. The company had revenue of $786.90 million during the quarter, compared to the consensus estimate of $794.93 million. During the same period in the prior year, the company earned $1.01 EPS. Endo International’s revenue was down 11.0% on a year-over-year basis. sell-side analysts anticipate that Endo International will post 3.67 EPS for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of ENDP. Schroder Investment Management Group purchased a new stake in shares of Endo International in the second quarter worth approximately $330,000. Systematic Financial Management LP lifted its position in shares of Endo International by 14.6% in the second quarter. Systematic Financial Management LP now owns 149,485 shares of the company’s stock worth $1,670,000 after purchasing an additional 19,065 shares in the last quarter. Riverhead Capital Management LLC lifted its position in shares of Endo International by 64.4% in the second quarter. Riverhead Capital Management LLC now owns 15,025 shares of the company’s stock worth $168,000 after purchasing an additional 5,887 shares in the last quarter. Teachers Advisors LLC lifted its position in shares of Endo International by 1.9% in the second quarter. Teachers Advisors LLC now owns 840,470 shares of the company’s stock worth $9,388,000 after purchasing an additional 15,928 shares in the last quarter. Finally, TIAA CREF Investment Management LLC lifted its position in shares of Endo International by 1.6% in the second quarter. TIAA CREF Investment Management LLC now owns 649,535 shares of the company’s stock worth $7,255,000 after purchasing an additional 10,387 shares in the last quarter. 93.06% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another publication, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.com-unik.info/2018/01/11/cantor-fitzgerald-analysts-give-endo-international-endp-a-7-00-price-target.html.

About Endo International

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Analyst Recommendations for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit